The studies of Yan et al. also demonstrated that BRAF and MEK inhibitor-treated patients, showing complete responses, have preexisting tumor immunity transcriptomic signatures that are higher than those expressed in patients with progressive disease, suggesting that enriched immune infiltration improves response to BRAFi and MEKi combination (40). Here, BRAF is linked to neoplasm.